MGNX
MacroGenics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$212.91M
P/E Ratio
—
EPS
$-1.18
Beta
1.10
52W High
$3.54
52W Low
$1.10
50-Day MA
$2.30
200-Day MA
$1.77
Dividend Yield
—
Profit Margin
-49.90%
Forward P/E
60.98
PEG Ratio
0.01
About MacroGenics Inc
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Fundamentals
| Revenue (TTM) | $149.50M |
| Gross Profit (TTM) | $-33.68M |
| EBITDA | $-65.67M |
| Operating Margin | -29.30% |
| Return on Equity | -87.00% |
| Return on Assets | -17.60% |
| Revenue/Share (TTM) | $2.37 |
| Book Value | $0.88 |
| Price-to-Book | 3.52 |
| Price-to-Sales (TTM) | 1.42 |
| EV/Revenue | 0.285 |
| EV/EBITDA | -1.54 |
| Quarterly Earnings Growth (YoY) | -70.40% |
| Quarterly Revenue Growth (YoY) | 113.00% |
| Shares Outstanding | $63.56M |
| Float | $55.59M |
| % Insiders | 3.06% |
| % Institutions | 64.56% |
Analyst Ratings
Consensus ($3.60 target)
1
Strong Buy1
Buy5
HoldData last updated: 4/8/2026